juste ça même si pas important!
NicOx S.A. (NYSE Euronext Paris: COX) today announced that the European
Medicines Agency (EMEA) has validated the Marketing Authorization
Application (MAA) for naproxcinod, which was submitted through the
centralized procedure in December 2009.